Bemarituzumab Biosimilar – Anti-FGFR2 mAb – Research Grade

Bemarituzumab Biosimilar – Anti- FGFR2 mAb – Research Grade

About Bemarituzumab biosimilar

Bemarituzumab is a humanized monoclonal antibody targeting the human fibroblast growth factor receptor 2b (FGFR2b). This humanized glycosylated biosimilar belong to the family of immunoglobulin G1- type. It blocks FGF ligand binding to the receptor, which causes the inhibition of downstream signaling pathways and promotes Antibody-dependent cell-mediated cytotoxicity (ADCC). Bemarituzumab induces receptor internalization and degradation.

About FGFR2b and FGF/FGFR pathway

FGFR2b is an isoform of fibroblast growth factor receptors. They are four signaling tyrosine kinase FGF receptors mediating interactions between cytosolic environment and mesenchyme. Activated FGFRs can phosphorylate tyrosine residues which are mediating specifically interaction with cytosolic adaptor proteins. FGFR2b receptor is overexpressed in 30% of HER2-negative Gastric and Gastroesophageal Cancers. Bemarituzumab is designed to target these specific cancer subtypes, which are using the FGF/FGFR pathway to promote transformation and proliferation of cells into tumors and to promote angiogenesis.

A research grade biosimilar

Bemarituzumab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use.